Generate:Biomedicines pricing
The platform is not licensed: the commercial surface is the company's own pipeline plus confidential collaboration programs with Amgen and Novartis, first announced in January 2022 and September 2024. Chroma's code and model weights are released at no cost to academic researchers and non profit entities.
How Generate:Biomedicines pricing works
- Pricing model
- The platform is not sold. The company develops its own pipeline and runs confidential collaboration programs with Amgen and Novartis. Chroma is released separately as open source at no cost to academic and non profit users.
As a listed company (Nasdaq: GENB, trading since February 2026) Generate reports its own financial results quarterly, which describe the company's economics rather than a price a partner can apply. Collaboration terms, and how rights to platform designed molecules are split, are not public.
Generate:Biomedicines pricing against its alternatives
Published prices for Generate:Biomedicines and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.
- GGenerate:BiomedicinesNot applicable
- AAbsciNo published price
- PProfluentOpenCRISPR-1 free to license, other terms not published
- IIsomorphic LabsNot applicable
- NNabla BioNo published price
- BBigHat BiosciencesNo published price
- IInsilico MedicineNo published price
- GGaluxNo published price
- EEarendil LabsNo published price
Generate:Biomedicines pricing, answered
How much does Generate:Biomedicines cost?
Generate:Biomedicines does not publish a price. The platform is not licensed: the commercial surface is the company's own pipeline plus confidential collaboration programs with Amgen and Novartis, first announced in January 2022 and September 2024. Chroma's code and model weights are released at no cost to academic researchers and non profit entities.